

Receipt

CASE 4-100-8303C/C1D1

## CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Angela L. Gehring  
Type or print nameAngela L. Gehring  
SignatureMay 3, 2001  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
SCHULER ET AL.

Art Unit: 1714

APPLICATION NO: 10/092,639

FILED: MARCH 7, 2002

FOR: USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND  
XENOTRANSPLANTATIONAssistant Commissioner for Patents  
Washington, D.C. 20231RECEIVED  
MAY 22 2002  
TC 1700LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists Title. Please issue a corrected filing receipt listing the Title as follows:

--Use of rapamycin derivatives in vasculopatheis and xenotransplantation--

A copy of the filing receipt with the correction noted is enclosed.

Applicants believe this error is ascribable to the Patent Office. Accordingly, no fees are required. However, if this is incorrect, the Commissioner is hereby authorized to charge the \$25 fee under 37 CFR \$1.19(h) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6765

Date: May 2, 2002

Thomas R. Savitsky  
Thomas R. Savitsky  
Attorney for Applicants  
Reg. No. 31,661




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/092,639	03/07/2002	1714	740	4-100-8303C	CIDI	18	2

001095  
THOMAS HOXIE  
NOVARTIS CORPORATION  
PATENT AND TRADEMARK DEPT  
564 MORRIS AVENUE  
SUMMIT, NJ 079011027



CONFIRMATION NO. 8447

## FILING RECEIPT



\*OC000000007840825\*

TRS

SV

Date Mailed: 04/10/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Walter Schuler, Grenzach-Wyhlen, GERMANY; ✓  
Hendrik J. Schuurman, Basel, SWITZERLAND; ✓  
Gisbert Weckbecker, Biel-Benken, SWITZERLAND; ✓  
Hans-Gunter Zerwes, Lorrach, GERMANY; ✓

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/712,359 11/14/2000 ✓  
WHICH IS A CON OF 09/155,210 09/23/1998 ABN ✓  
WHICH IS A 371 OF PCT/EP97/01548 03/26/1997 ✓

## Foreign Applications

UNITED KINGDOM 9606452.2 03/27/1996

If Required, Foreign Filing License Granted 04/10/2002

Projected Publication Date: 07/18/2002


Non-Publication Request: No

Early Publication Request: No

Title

RECEIVED  
MAY 22 2002  
TC 1700

Use of rapamycin derivatives in vasculopatheis and xenotransplantation

COPY OF PAPERS  
ORIGINALLY FILEDPreliminary Class  
252

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

RECEIVED  
MAY 22 2002  
TC 1700